Speaker illustration

Doctor Michele Russo

Molecular Biotechnology Centre, Turin (Italy)

Member of:

Heart Failure Association

Dr. Michele Russo got his MSc in 2015 at the University of Naples “Federico II”, Naples, Italy, where he got a strong background in Molecular Immuno-Oncology. Since 2016 he is PhD student in the Department of Translational Medical Sciences, University of Naples “Federico II”, on cardiovascular diseases and heart failure. His ongoing studies in the emerging field of Cardio-Oncology, under the supervision of Prof. Carlo Gabriele Tocchetti, brought him to investigate the effect of chemotherapy regimens on both cancer progression and heart function. The main goal of his current research is to understand the events, promoted by chemotherapy and leading to cardiac dysfunction, with the aim of developing new therapeutic strategies to prevent antineoplastic-induced cardiotoxicity.

The novel butyrate derivative phenylalanine-butyramide protects from doxorubicininduced cardiotoxicity

Event: Heart Failure 2019

Topic: Heart Failure

Session: Basic Science- Metabolism

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb